DUBLIN - The Board of Horizon Therapeutics plc confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi which may or may not lead to an offer being made for the entire share capital of the company.
The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the Clinical Trials on Alzheimer's Disease meeting in San Francisco.
Almost all of the drug industry’s biggest advertisers cut their spending on Twitter to zero or near-zero over the last two weeks amid worries about impersonation of their brands by pranksters and the future of the social media company.